Unusual case of duodenobiliary fistula complicating Crohn's disease successfully treated with Adalimumab.

Abstract

Crohn's disease (CD) is characterized by transmural inflammation of the gastrointestinal tract, which predisposes to the formation of fistula. Duodenal involvement occurs in less than 5% of cases and often leads to clinically relevant strictures. However, fistula formation in the duodenum is exceptional. Herein, we report an unusual case of duodenobiliary fistula due to CD occurring in a 65-year-old patient who was successfully treated by anti-tumor necrosis factor (TNF) agents. This case report highlights the efficacy of anti-TNF alpha agents in the treatment of a bilioenteric fistula because it increases the probability of clinical remission and mucosal healing and therefore reduces the need for surgical treatment which may be associated morbidity.

• Authors: Aya Hammami, Aida Ben Slama, Hanen Jaziri, Wafa Ben Ameur, Imed Ben Mansour, Ahlem Brahem, Salem Ajmi, Hela Jemni, Mehdi Ksiaa, Ali Jmaa
• Journal: Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology (Arab J Gastroenterol) Vol. 17 Issue 4 Pg. 188-190 (Dec 2016) ISSN: 2090-2387 [Electronic] Egypt
• PMID: 27939339 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2016 Pan-Arab Association of Gastroenterology. Published by Elsevier B.V. All rights reserved.

Chemical References

• Anti-Inflammatory Agents
• Adalimumab

Topics

• Adalimumab (therapeutic use)
• Aged
• Anti-Inflammatory Agents (therapeutic use)
• Bile Duct Diseases (complications, drug therapy)
• Biliary Fistula (complications, drug therapy)
• Crohn Disease (complications, drug therapy)
• Duodenal Diseases (complications, drug therapy)
• Female
• Humans
• Intestinal Fistula (complications, drug therapy)